Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | GYS1 | P13807 | 12/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118961 | 1.00 | SPHK2 (0.41) | SPHK2SPHK1GYS1HCRTR1HCRTR2 | |
| SCHEMBL23926339 | 0.89 | SPHK2 (0.42) | SPHK2SPHK1GYS1HCRTR1HCRTR2 | |
| SCHEMBL30118942 | 0.89 | SPHK2 (0.42) | SPHK2SPHK1GYS1HCRTR1HCRTR2 | |
| SCHEMBL23926331 | 0.84 | MEN1 (0.44) | SPHK2SPHK1HCRTR1HCRTR2APP | |
| SCHEMBL23926386 | 0.82 | GHSR (0.37) | SPHK2SPHK1GYS1HCRTR1HCRTR2 | |
| SCHEMBL30369527 | 0.82 | GHSR (0.37) | SPHK2SPHK1GYS1HCRTR1HCRTR2 | |
| SCHEMBL23926332 | 0.80 | APP (0.44) | APP | |
| SCHEMBL30118914 | 0.79 | KLK7 (0.52) | — | |
| SCHEMBL23926370 | 0.79 | KLK7 (0.52) | — | |
| SCHEMBL24127946 | 0.77 | KLK7 (0.49) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | SPHK2 3695/4885SPHK1 3167/4885GYS1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.